iPS cell transplants show early promise for treating Parkinson’s disease safely
In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with Parkinson’s disease and observed promising motor improvements with no serious safety concerns over 24 months. The therapy…